PCV

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

Retrieved on: 
Thursday, May 5, 2022
Drug development, Ranibizumab, Investment, VEGF, Department, Nasdaq, CNV, GLOBE, DME, Shore, Company, Safety, ARVO, Research, Fluorescein angiography, Poster, New York University Grossman School of Medicine, Patient, Association, Program, Diabetic retinopathy, Retina, COAST, PCV, Overalls, Industry, Patent, Association for Research in Vision and Ophthalmology, MD, Database, NYU, Private Securities Litigation Reform Act, Visual acuity, SD, SEC, ID, CEO, Technology, AMD, Annual general meeting, ASX, Pharmaceutical industry, Ophthalmology

The presentation, titled Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy, was held on Sunday, May 1, 2022, and appeared in a session on clinical and translational research and AMD therapies excluding anti-VEGF.

Key Points: 
  • The presentation, titled Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy, was held on Sunday, May 1, 2022, and appeared in a session on clinical and translational research and AMD therapies excluding anti-VEGF.
  • Dr. Jason Slakter, MD, Clinical Professor, Department of Ophthalmology at NYU Grossman School of Medicine, presented.
  • The ARVO poster presented results of a pre-specified subgroup analysis of subjects with Polypoidal Choroidal Vasculopathy (PCV type CNV) enrolled in the Phase 2b randomized, sham-controlled study of patients with treatment naive exudative AMD.
  • In this study, subjects received either monotherapy with ranibizumab (Lucentis) or combination therapy with ranibizumab and one of two doses of OPT-302.

Vaxcyte to Participate in Upcoming Investor Conferences in May

Retrieved on: 
Tuesday, May 3, 2022
Sutro Biopharma, GLOBE, Company, Webcast, Periodontal disease, PCV, Vaccine, Antigen, Infection, Pneumonia, SAN, Genetically modified bacteria, Investor

ET / 2:40 p.m. PT and one-on-one meetings on Tuesday, May 10 and Wednesday, May 11.

Key Points: 
  • ET / 2:40 p.m. PT and one-on-one meetings on Tuesday, May 10 and Wednesday, May 11.
  • A live webcast of the fireside chat can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

Retrieved on: 
Friday, April 29, 2022
Patent, Program, CEO, Retina, Overalls, Association, Patient, Investment, GLOBE, Research, DME, ASX, Ranibizumab, Database, Technology, MD, Company, PCV, AMD, Private Securities Litigation Reform Act, Drug development, VEGF, NASDAQ, Diabetic retinopathy, Association for Research in Vision and Ophthalmology, Industry, SEC, ARVO, Safety, Pharmaceutical industry, Ophthalmology

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, CO from May 1-4, 2022 and virtually from May 11-12, 2022.

Key Points: 
  • MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, CO from May 1-4, 2022 and virtually from May 11-12, 2022.
  • Details for the poster presentation are as follows:
    The ARVO annual conference is recognized as one of the worlds top medical meetings.
  • With more than 10,000 ARVO members worldwide, the annual ARVO meeting hosts leading scientific researchers, clinical investigators and clinicians involved in the ophthalmic industry.
  • Authorized for release to ASX by Megan Baldwin, CEO & Managing Director
    Join our email database to receive program updates:

Gynecology Drugs Global Market Report 2022: A $33.21 Billion Market in 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 8, 2022
Pharmaceutical, Health, Women, Consumer, Adoption, Therapy, CAGR, Ludwig Cancer Research, Curcumin, Ocimum tenuiflorum, Asia-Pacific, University, PCV, Yoga, Trial of the century, Growth, Cancer, Clinical trial, Geography, Homeopathy, Gynecologic cancer disparities in the United States, Forecasting, Woman, Incidence, Medicine, Precision medicine, Acupuncture, GDP, Ovarian cancer, Technology, Cervical ectropion, RNA transfection, COVID-19, Distribution, Patient, Merck, Medicinal plants, Pharmaceutical industry, Retail, Ayurveda

The "Gynecology Drugs Global Market Report 2022: By Therapeutics, By Indication, By Distribution" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gynecology Drugs Global Market Report 2022: By Therapeutics, By Indication, By Distribution" report has been added to ResearchAndMarkets.com's offering.
  • The global gynecology drugs market is expected to grow from $24.68 billion in 2021 to $26.36 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%..
  • Key financial deals which have shaped the market in recent years are identified
    The gynecology drugs market section of the report gives context.
  • It compares the gynecology drugs market with other segments of the gynecology drugs market by size and growth, historic and forecast.

HCAP Partners Announces the Addition of Tom Woelfel as Senior Director of Impact

Retrieved on: 
Thursday, April 7, 2022
Public policy, University of California, Davis, PVC, PCV, Job (biblical figure), Growth, Joseph Woelfel, Research, LMI, Working Group, Workforce, Managerial economics, Sustainability, Software, Industry, Interest group, Socially responsible investing, HCAP, COVID-19, US, SAN, The Glass Closet: Why Coming Out Is Good Business, University, Policy, Risk management, Renewable energy, Management, Science

SAN DIEGO, April 7, 2022 /PRNewswire/ -- HCAP Partners, a California-based private equity firm and nationally recognized impact investor, today announced that Tom Woelfel has joined the firm as Senior Director of Impact.

Key Points: 
  • Tom Woelfel to lead HCAP's efforts to scale the Gainful Jobs Approach, deepen its impact management efforts, and participate in knowledge building across the impact investing space
    SAN DIEGO, April 7, 2022 /PRNewswire/ -- HCAP Partners , a California-based private equity firm and nationally recognized impact investor, today announced that Tom Woelfel has joined the firm as Senior Director of Impact.
  • Tom joined HCAP Partners to lead the Gainful Jobs Approach and overall impact management efforts, partnering with HCAP portfolio companies and collaborating with limited partners and industry thought leaders to improve job quality and generate positive impact in LMI communities.
  • Prior to joining HCAP Partners, Tom served for over a decade as Director of Pacific Community Ventures' research and consulting practice focused on supporting the growth and efficacy of impact investing.
  • In addition to advising impact investing clients, Tom led PCV's work to improve job quality and developed Good Jobs, Good Business , a job quality toolkit for small businesses.

Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 5, 2022
Company, Investor, PCV, Genetically modified bacteria, Vaccine, Infection, Conference, Antigen, Webcast, Sutro Biopharma, Periodontal disease, GLOBE, SAN, Pneumonia

A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .

Key Points: 
  • A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .
  • A replay of the webcast will be available for approximately 30 days following the conference.
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

Retrieved on: 
Monday, April 4, 2022
Company, Meningitis, Private Securities Litigation Reform Act, Vaccination, PCV, Trial of the century, Otitis media, Immunodeficiency, Public health, Mortality, Bacteria, Genetically modified bacteria, Vaccine, Streptococcus, Streptococcus pneumoniae, SEC, Sinusitis, Infection, IPD, PD, Subclinical infection, Antigen, OPA, Incidence, Immunoglobulin G, Death, Achievement, Sutro Biopharma, U.S. Securities and Exchange Commission, Periodontal disease, Security (finance), Safety, Review, GLOBE, Disease, Inactivated vaccine, Chemistry, SAN, Annual report, Data monitoring committee, Pneumonia, Pharmaceutical industry, COVID-19, Pneumococcal conjugate vaccine

SAN CARLOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the first participants were dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical study evaluating VAX-24 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults. The initiation of the Phase 2 portion of the study in healthy adults 50 to 64 years of age occurred after the independent Data Monitoring Committee completed a prespecified review of Phase 1 safety and tolerability data and recommended that the study progress as planned. The Company expects to announce topline safety, tolerability and immunogenicity results from both the Phase 1 and Phase 2 portions of the VAX-24 study by the end of 2022.

Key Points: 
  • The Company expects to announce topline safety, tolerability and immunogenicity results from both the Phase 1 and Phase 2 portions of the VAX-24 study by the end of 2022.
  • Moving forward with the larger Phase 2 portion of the VAX-24 Phase 1/2 study is an exciting step toward delivering potential clinical proof-of-concept data for our lead, 24-valent PCV candidate, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • The VAX-24 Phase 1/2 clinical proof-of-concept study is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults (NCT05266456).
  • Readers should not rely upon the information in this press release as current or accurate after its publication date.

Tallysight Closes Strategic Financing Round, Adds Leaders in Sports, Media and Technology to Advisory Board

Retrieved on: 
Tuesday, March 22, 2022
The Buffalo News, Former, Turner Sports, Leadership, PCV, True Crime Network, Growth, CMO, ESPN, The Weather Channel, Name, The Dallas Morning News, National Geographic, Global, Industry, Technology, SB Nation, Weather, Ecosystem, Global Gaming Expo, GLOBE, SportsCenter, NASCAR, National Geographic (American TV channel), Catena Media, Sport, SAN, Dallas, Publishing, Video game, Sportradar

The round is being led by Phoenix Capital Ventures (PCV) and includes several prominent investors from technology, sports, and media.

Key Points: 
  • The round is being led by Phoenix Capital Ventures (PCV) and includes several prominent investors from technology, sports, and media.
  • The firm also announced three new members of their Advisory board that will help guide the company's leadership as it experiences rapid growth.
  • Tallysight's first-of-its-kind digital publishing toolkit provides seamless ways for content creators - from individuals to large-scale publishers - to effortlessly develop, distribute, and monetize social sports gaming content.
  • The no-code, white-labeled platform allows publishers to automate and seamlessly integrate social gaming content - like expert picks, leaderboards, and affiliate monetization experiences - into their digital media and social channels.

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, February 28, 2022
Tolerability, Key, Security (finance), ID, Immunoglobulin G, Company, Sutro Biopharma, Periodontal disease, Antigen, Senior, IND, Private Securities Litigation Reform Act, R, Chemistry, Host, Board of directors, Board, Investment, Safety, U.S. Securities and Exchange Commission, Exercise, Food, Bacteria, SAN, End, PCV, Insurance, Population, Regulation of tobacco by the U.S. Food and Drug Administration, Administration, OPA, G&A, Infection, Trial of the century, Vaccine, Genetically modified bacteria, IPD, Streptococcus, GLOBE, Commercial, GMP, Pneumonia, Investor, Achievement, Webcast, Research and development, Annual report, Chairperson, Ageing, Adult, FDA, Conference, General Administration of Sport of China, SEC, Communications satellite, Pharmaceutical industry, Lithium, COVID-19, Pneumococcal conjugate vaccine

SAN CARLOS, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
  • Completed the Manufacture of VAX-24 Drug Product: In the fourth quarter of 2021, Vaxcyte completed all steps in the manufacturing process, including formulation, fill and finish, along with the testing and release, for the VAX-24 drug product.
  • Following the nomination of its final VAX-A1 vaccine candidate in the first quarter of 2021, the Company initiated IND-enabling studies in the second half of 2021.
  • Strengthened Leadership Team and Board of Directors with Key Appointments: During 2021, Vaxcyte added several key leaders to its executive team and Board of Directors.

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Streptococcus pneumoniae, PCV, Pneumonia, Tolerability, Inactivated vaccine, Public health, Security (finance), OPA, Immunodeficiency, Otitis media, PD, Immunogenicity, Immunoglobulin G, Company, Sutro Biopharma, Antigen, Periodontal disease, Subclinical infection, Infection, U.S. Securities and Exchange Commission, Trial of the century, Vaccine, Sinusitis, Genetically modified bacteria, Bacteria, Disease, Meningitis, Private Securities Litigation Reform Act, SAN, IPD, Death, Streptococcus, Chemistry, Incidence, Mortality, SEC, Pharmaceutical industry, COVID-19, Pneumococcal conjugate vaccine, Safety

SAN CARLOS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the first participants were dosed in the Phase 1/2 clinical study of VAX-24. This clinical proof-of-concept study will evaluate the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumonia in adults. The Company expects to announce topline safety, tolerability and immunogenicity results from the Phase 1/2 study by the end of 2022.

Key Points: 
  • This clinical proof-of-concept study will evaluate the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumonia in adults.
  • The Company expects to announce topline safety, tolerability and immunogenicity results from the Phase 1/2 study by the end of 2022.
  • The VAX-24 Phase 1/2 clinical proof-of-concept study is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults.
  • Vaxcytes lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of IPD and pneumonia.